Last updated on February 2020

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Brief description of study

To show the superiority in safety of Smoflipid over Intralipid as measured by the number of study patients in each treatment group with conjugated bilirubin exceeding 2 mg/dL during the first 28 days of study treatment, confirmed by a second sample collected 7 days after the first sample.

Clinical Study Identifier: NCT02579265

Find a site near you

Start Over

Boston Children's Hospital

Boston, MA United States
  Connect »